CVE:ATE - Antibe Therapeutics Stock Price, News & Analysis

C$0.38
-0.01 (-2.53 %)
(As of 09/17/2019 04:00 PM ET)
Today's Range
C$0.38
Now: C$0.39
C$0.40
50-Day Range
C$0.28
MA: C$0.37
C$0.46
52-Week Range
C$0.24
Now: C$0.39
C$0.47
Volume408,156 shs
Average Volume638,342 shs
Market CapitalizationC$104.04 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Antibe Therapeutics Inc., a pharmaceutical development company, originates, develops, and out-licenses patent protected pharmaceuticals in Canada, Europe, and the United States. Its drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. The company's lead compound is ATB-346, a hydrogen sulfide-releasing derivative of naproxen for treating rheumatoid arthritis, ankylosing spondylitis, and general pain reduction, which has completed Phase IIB gastrointestinal safety study. Its products also comprise ATB-352, which is in preclinical stage for the treatment of gout, dental pain, post-surgical pain, etc.; and ATB-340 that is in preclinical development stage for the treatment of cardiovascular disease and cancer chemoprevention. In addition, it offers various tissue regenerating products, such as bone grafting and dental membrane solutions for the dental and orthopedic markets; and surgical instruments for dental surgery, plastic surgery, general surgery and specialties, and veterinary applications. The company was incorporated in 2009 and is headquartered in Toronto, Canada.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-905-5705103

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesC$9.76 million
Cash FlowC$0.01 per share
Book ValueC$0.02 per share

Profitability

Miscellaneous

Employees37
Market CapC$104.04 million
Next Earnings Date11/22/2019 (Estimated)
OptionableNot Optionable

Receive ATE News and Ratings via Email

Sign-up to receive the latest news and ratings for ATE and its competitors with MarketBeat's FREE daily newsletter.


Antibe Therapeutics (CVE:ATE) Frequently Asked Questions

What is Antibe Therapeutics' stock symbol?

Antibe Therapeutics trades on the Canadian Venture Exchange (CVE) under the ticker symbol "ATE."

How were Antibe Therapeutics' earnings last quarter?

Antibe Therapeutics Inc (CVE:ATE) released its quarterly earnings data on Tuesday, August, 27th. The company reported ($0.01) EPS for the quarter, meeting the Zacks' consensus estimate of ($0.01). The firm earned $2.76 million during the quarter, compared to the consensus estimate of $2.40 million. View Antibe Therapeutics' Earnings History.

When is Antibe Therapeutics' next earnings date?

Antibe Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, November 22nd 2019. View Earnings Estimates for Antibe Therapeutics.

Has Antibe Therapeutics been receiving favorable news coverage?

News coverage about ATE stock has trended negative recently, InfoTrie reports. The research firm ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Antibe Therapeutics earned a coverage optimism score of -2.9 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the next several days. View News Stories for Antibe Therapeutics.

Who are some of Antibe Therapeutics' key competitors?

What other stocks do shareholders of Antibe Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Antibe Therapeutics investors own include Resverlogix (RVX), Terra Tech (TRTC), Green Bancorp (GNBC), Cartier Iron (CFE), Scorpio Gold (SGN), Nemaska Lithium (NMX), Cronos Group (CRON), Great Thunder Gold (GTG), Cronos Group (MJN) and Crescent Point Energy (CPG).

Who are Antibe Therapeutics' key executives?

Antibe Therapeutics' management team includes the folowing people:
  • Mr. Daniel Marcel Legault, Pres, CEO, Sec. & Director (Age 61)
  • Dr. John Lawrence Wallace, Founder, Chief Scientific Officer & Director (Age 62)
  • Mr. Alain Wilson MBA, Chief Financial Officer
  • Mr. Scott Curtis M.Eng, CFA, VP of Corp. Devel.
  • Dr. David James Vaughan Ph.D., Chief Devel. Officer (Age 69)

How do I buy shares of Antibe Therapeutics?

Shares of ATE and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Antibe Therapeutics' stock price today?

One share of ATE stock can currently be purchased for approximately C$0.39.

How big of a company is Antibe Therapeutics?

Antibe Therapeutics has a market capitalization of C$104.04 million and generates C$9.76 million in revenue each year. Antibe Therapeutics employs 37 workers across the globe.View Additional Information About Antibe Therapeutics.

What is Antibe Therapeutics' official website?

The official website for Antibe Therapeutics is http://www.antibethera.com/.

How can I contact Antibe Therapeutics?

Antibe Therapeutics' mailing address is 15 Prince Arthur Ave, TORONTO, ON M5R 1B2, Canada. The company can be reached via phone at +1-905-5705103.


MarketBeat Community Rating for Antibe Therapeutics (CVE ATE)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  134 (Vote Outperform)
Underperform Votes:  104 (Vote Underperform)
Total Votes:  238
MarketBeat's community ratings are surveys of what our community members think about Antibe Therapeutics and other stocks. Vote "Outperform" if you believe ATE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/17/2019 by MarketBeat.com Staff

Featured Article: Candlestick

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel